In view of these findings, we have focused our work on the discovery of a cell-permeable and selective small molecule inhibitor of ST6GAL1 for use as an experimental tool compound and as a lead for the further development of a preclinical cancer drug candidate. This evidence concerns the gene ST6GAL1 and cancer.